To date, to overcome the lack of clinical predictive immune biomarkers, and considering that PDL1, TMB, and MSI are not useful in sarcoma, and in particular LMS, the promising predictive immune biomarker of TLS currently under clinical investigation requires expertise from sarcoma pathologists and inter- and intra-observer variability may not be precluded. Here, CD274 is linked to sarcoma.